Expression and reactivation of HIV in a chemokine induced model of HIV latency in primary resting CD4+ T cells.
about
HIV restriction in quiescent CD4⁺ T cellsThe immunological synapse: the gateway to the HIV reservoirRecent developments in human immunodeficiency virus-1 latency researchAn in-depth comparison of latent HIV-1 reactivation in multiple cell model systems and resting CD4+ T cells from aviremic patientsActivation of HIV transcription with short-course vorinostat in HIV-infected patients on suppressive antiretroviral therapyDirectly infected resting CD4+T cells can produce HIV Gag without spreading infection in a model of HIV latencyA Subset of Latency-Reversing Agents Expose HIV-Infected Resting CD4+ T-Cells to Recognition by Cytotoxic T-Lymphocytes.The CCR5-antagonist Maraviroc reverses HIV-1 latency in vitro alone or in combination with the PKC-agonist Bryostatin-1HIV persistence: chemokines and their signalling pathways.Entinostat is a histone deacetylase inhibitor selective for class 1 histone deacetylases and activates HIV production from latently infected primary T cells.Immune activation and HIV persistence: implications for curative approaches to HIV infection.Dendritic cell-induced activation of latent HIV-1 provirus in actively proliferating primary T lymphocytesAttenuated Listeria monocytogenes vectors overcome suppressive plasma factors during HIV infection to stimulate myeloid dendritic cells to promote adaptive immunity and reactivation of latent virus.Myeloid dendritic cells induce HIV-1 latency in non-proliferating CD4+ T cells.Role of myeloid cells in HIV-1-host interplay.Glut1-mediated glucose transport regulates HIV infection.Understanding Factors That Modulate the Establishment of HIV Latency in Resting CD4+ T-Cells In Vitro.Temporal transcriptional response to latency reversing agents identifies specific factors regulating HIV-1 viral transcriptional switchImmunological biomarkers predict HIV-1 viral rebound after treatment interruptionIn Vitro Reactivation of Replication-Competent and Infectious HIV-1 by Histone Deacetylase Inhibitors.Peripheral T Follicular Helper Cells Are the Major HIV Reservoir within Central Memory CD4 T Cells in Peripheral Blood from Chronically HIV-Infected Individuals on Combination Antiretroviral Therapy.A Subset of CD4/CD8 Double-Negative T Cells Expresses HIV Proteins in Patients on Antiretroviral Therapy.Cell-associated HIV RNA: a dynamic biomarker of viral persistence.LEDGIN-mediated Inhibition of Integrase-LEDGF/p75 Interaction Reduces Reactivation of Residual Latent HIVAltering cell death pathways as an approach to cure HIV infection.The differential short- and long-term effects of HIV-1 latency-reversing agents on T cell functionThe role of cytokines in the establishment, persistence and eradication of the HIV reservoirHIV-1 infection, response to treatment and establishment of viral latency in a novel humanized T cell-only mouse (TOM) model.Is specific HIV eradication from the brain possible or needed?Cellular and molecular mechanisms involved in the establishment of HIV-1 latency.From reactivation of latent HIV-1 to elimination of the latent reservoir: the presence of multiple barriers to viral eradication.HIV-1 latency: an update of molecular mechanisms and therapeutic strategies.IFITM1 targets HIV-1 latently infected cells for antibody-dependent cytolysis.Solution Structure of CCL19 and Identification of Overlapping CCR7 and PSGL-1 Binding Sites.Establishment and Reversal of HIV-1 Latency in Naive and Central Memory CD4+ T Cells In Vitro.Pharmacologic HIV-1 Nef blockade promotes CD8 T cell-mediated elimination of latently HIV-1-infected cells in vitro.Crosstalk between histone modifications indicates that inhibition of arginine methyltransferase CARM1 activity reverses HIV latency.Kinetics of HIV-1 Latency Reversal Quantified on the Single-Cell Level Using a Novel Flow-Based TechniqueLatent HIV-1 can be reactivated by cellular superinfection in a Tat-dependent manner, which can lead to the emergence of multidrug-resistant recombinant viruses.Comparison of HDAC inhibitors in clinical development: effect on HIV production in latently infected cells and T-cell activation.
P2860
Q26995784-51070313-17EE-433F-AC54-BA4EDD6C898EQ27002959-35CAB2EF-CF95-49AD-91F5-0AC0F67AFC2EQ27013114-46D4A227-E762-40EB-A916-6C030A775569Q28538015-626A346E-8FD1-408C-B254-DD1CC770E90FQ28544949-A7A286C6-C4D8-46BC-85BB-80EF174404E3Q28728736-6AC6E6CA-675E-4BF1-9314-E5B714E2C7C6Q30385378-7B64CD49-B8FA-4726-B501-CB2BDF0BB90CQ33725916-CC7BD643-5E38-4CF1-B2DE-D5DDA652F873Q33774665-4CED6816-78BA-45F2-910F-23E09B735745Q33838633-8E4A02E3-F3A3-4AFF-BC76-D2E3F1AC506EQ34351320-6C2102D2-E6B5-44F5-90C8-4361C0DC925EQ34649701-EED1AE1A-E7CA-4311-94EE-0416E734CDE5Q34871958-5E0619F0-7AFF-4E78-9F04-F7660BF6D1B9Q35067224-C2CFF138-1E29-4112-B713-4E97FE0D4BB9Q35196505-800E7A70-C476-417D-A047-CA8D35851C1FQ35787190-3EFC62C1-BB70-448E-AECE-6314BD8E72CEQ36068841-53460445-3708-4662-8D3C-4E7E97AA5233Q36125264-C68A1E5A-B0BC-41DE-873C-5A8A1961962BQ36250043-24C054A2-EDEE-4E78-8041-FC0CAC615F86Q36523946-8959AC62-1FE4-4CDD-8D42-1A86A0137252Q36736667-4736A963-8E43-4CC1-8D49-DA40DD8EDF51Q36736780-31BECA6A-664C-4082-8F5D-D3A7CB278470Q36798408-A979235A-4108-4C04-9565-389744E2C70BQ37035177-EFA4F31E-CC40-4F98-8DD8-254D55D473B0Q37062057-2D877303-17A5-4ADC-A150-01C60C4B5296Q37144949-6658DE2F-A325-40F4-B7B4-81C77F3125BEQ37157209-E3373FC9-D803-4C93-AB1F-6CED8D7492B6Q37305858-56C0176C-30CE-46CC-A0FB-17144EF50A92Q38071699-1E96ED87-26EE-4062-AFD1-BB2A9FF21043Q38078562-30F7A9D9-E599-44D0-BABD-BBD21963EB76Q38101294-B2F45AAE-4D5F-4632-A03D-F97C6115C041Q38204866-3D3D3B32-0D0E-4A17-A0EC-52C0D47D7BB4Q38720858-7CD1DBC4-793D-4DF0-8853-39C7484A34A4Q39546427-925D5E13-9FBB-41E1-99BA-DFF68AE17B02Q39645005-CCC8AA51-A8EA-4D69-A9ED-EB895C1BFD96Q40054912-8D962C5D-2C40-4314-9D1D-0E36FD8B41EFQ40150928-35ACC6F7-575D-41BE-9CAD-D330F3329247Q40597173-9E3811AE-B43F-47B3-9D69-7EAD033F61E1Q41760939-66587B84-86DE-4AF1-9283-5FE7CAB013C0Q41885967-79EC6E0B-4086-40DF-868B-10C9E1BB1DB2
P2860
Expression and reactivation of HIV in a chemokine induced model of HIV latency in primary resting CD4+ T cells.
description
2011 nî lūn-bûn
@nan
2011 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Expression and reactivation of ...... primary resting CD4+ T cells.
@ast
Expression and reactivation of ...... primary resting CD4+ T cells.
@en
type
label
Expression and reactivation of ...... primary resting CD4+ T cells.
@ast
Expression and reactivation of ...... primary resting CD4+ T cells.
@en
prefLabel
Expression and reactivation of ...... primary resting CD4+ T cells.
@ast
Expression and reactivation of ...... primary resting CD4+ T cells.
@en
P2093
P2860
P356
P1433
P1476
Expression and reactivation of ...... primary resting CD4+ T cells.
@en
P2093
Cândida Pereira
Damian Purcell
Fiona Wightman
Gabriela Khoury
Marina Alexander
Nitasha Kumar
Paul U Cameron
Saumya Ramanayake
Suha Saleh
P2860
P2888
P356
10.1186/1742-4690-8-80
P577
2011-10-12T00:00:00Z
P5875
P6179
1052756598